-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead Signs Licensing Deals With Three Generic Drugmakers for Investigational Ebola Drug Obeldesivir

PUBT·11/16/2026 21:11:41
Diffusion vocale
Gilead Signs Licensing Deals With Three Generic Drugmakers for Investigational Ebola Drug Obeldesivir
  • Gilead Sciences signed royalty-free licensing agreements with Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories for investigational Ebola drug obeldesivir.
  • The agreements cover 127 primarily low- and lower-middle-income countries, targeting potential access to obeldesivir for post-exposure prevention of Ebola Bundibugyo virus disease.
  • Manufacturing and supply depend on clinical data and regulatory authorizations; a Phase 3 trial is evaluating obeldesivir for this use.
  • Existing remdesivir licensing agreements are also being expanded to include filovirus disease, with potential access contingent on trial results and regulatory approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611161605BIZWIRE_USPR_____20261116_BW572571) on November 16, 2026, and is solely responsible for the information contained therein.